Clinical Features Comparing Arterial Thrombosis and Venous Thromboembolism in Hospitalized Patients with COVID-19: Result from the CLOT-COVID Study-Reference-Cited by-同舟云学术

Clinical Features Comparing Arterial Thrombosis and Venous Thromboembolism in Hospitalized Patients with COVID-19: Result from the CLOT-COVID Study

Published:2023-06-25 Issue:2 Volume:16 Page:115-123
ISSN:1881-641X
Container-title:Annals of Vascular Diseases
language:en
Short-container-title:Annals of Vascular Diseases

Author:

Umetsu Michihisa¹,Kanamori Hajime¹,Murakami Koji¹,Shiga Takuya¹,Yachi Sen²,Takeyama Makoto²,Nishimoto Yuji³,Tsujino Ichizo⁴,Nakamura Junichi⁴,Yamamoto Naoto⁵,Nakata Hiroko⁶,Ikeda Satoshi⁷,Aikawa Shizu⁸,Hayashi Hiroya⁹,Satokawa Hirono¹⁰,Okuno Yoshinori¹¹,Iwata Eriko¹²,Ogihara Yoshito¹³,Ikeda Nobutaka¹⁴,Kondo Akane¹⁵,Iwai Takehisa¹⁶,Yamada Norikazu¹⁷,Ogawa Tomohiro¹⁸,Kobayashi Takao⁵,Mo Makoto¹⁹,Yamashita Yugo¹¹

Affiliation:

1. Tohoku University Hospital

2. Japan Community Health Care Organization Tokyo Shinjuku Medical Center

3. Hyogo Prefectural Amagasaki General Medical Center

4. Hokkaido University Hospital

5. Hamamatsu Medical Center

6. Yokosuka General Hospital Uwamachi

7. Nagasaki University Hospital

8. Tsukuba Medical Center Hospital

9. Osaka Metropolitan University Graduate School of Medicine

10. Fukushima Medical University, School of Medicine

11. Kyoto University Hospital

12. Nankai Medical Center Japan Community Health Care Organization

13. Mie University Hospital

14. Toho University Ohashi Medical Center

15. Shikoku Medical Center for Children and Adults

16. Tsukuba Vascular Center

17. Kuwana City Medical Center

18. Fukushima Daiichi Hospital

19. Yokohama Minami Kyosai Hospital

Publisher

The Editorial Committee of Annals of Vascular Diseases

Subject

Pharmaceutical Science

Link

https://www.jstage.jst.go.jp/article/avd/16/2/16_oa.22-00112/_pdf

Reference24 articles.

1. 1) Sadeghipour P, Talasaz AH, Rashidi F, et al. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial. JAMA 2021; 325: 1620-30.

2. 2) Sholzberg M, Tang GH, Rahhal H, et al. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. BMJ 2021; 375: n2400.

3. 3) Spyropoulos AC, Goldin M, Giannis D, et al. Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial. JAMA Intern Med 2021; 181: 1612-20.

4. 4) Yamashita Y, Yachi S, Takeyama M, et al. Therapeutic-dose vs. prophylactic-dose anticoagulation therapy for critically ill patients with COVID-19 in a practice-based observational study. Circ J 2022; 86: 1137-42.

5. 5) Yamashita Y, Maruyama Y, Satokawa H, et al. Incidence and clinical features of venous thromboembolism in hospitalized patients with coronavirus disease 2019 (COVID-19). Circ J 2021; 85: 2208-14.